Healix

A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC)

Presented on October 7, 2015

Barry Statner, MD, CM FRCPC, FIDSA
Fernando S. Alvarado, MD, MPH, TM
Brian Metzger, MD, MPH
Richard M. Mandel, MD, FIDSA
Jorge R. Bernett, MD
H. Barry Baker, MD, FACP
Alfred E. Bacon III, MD
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

View Poster View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound